{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/melanoma-pigmented-lesions/supporting-evidence/evidence-on-the-abcd-7-point-checklists/","result":{"pageContext":{"chapter":{"id":"84e1f7c4-66db-59e5-b9a9-1fc097979aa4","slug":"evidence-on-the-abcd-7-point-checklists","fullItemName":"Evidence on the ABCD and 7-point checklists","depth":2,"htmlHeader":"<!-- begin field 4eb91fd9-0a92-4daa-9655-0f5c88ebcfb8 --><h2>Evidence on the ABCD and 7-point checklists</h2><!-- end field 4eb91fd9-0a92-4daa-9655-0f5c88ebcfb8 -->","summary":null,"htmlStringContent":"<!-- begin item 119afb2e-c40e-4d4b-9f85-9ca99b0b02e2 --><!-- begin field f21cc503-a029-462e-8fd6-d0515557fb7e --><p><strong>A number of studies have looked at different methods of diagnosing pigmented lesions but many have limitations for application in a primary care setting, such as Dermoscopy which is not commonly practised. The sensitivities and specificities of the 7-point checklist in comparison to the ABCD(E) rule has varied between studies, with the latter method still being commonly used in North America and Australia. The Weighted 7-point checklist is has been recommended by NICE since 2015 for practitioners in primary care in the UK to differentiate between benign lesions and suspected melanoma</strong> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/melanoma-pigmented-lesions/references/\">NICE, 2015b</a>]<strong>.</strong></p><ul><li>A non-comparative study prospectively assessed the sensitivity, specificity, and diagnostic accuracy of the 7-point checklist [<a class=\"bibliography-reference internal-reference\" href=\"/topics/melanoma-pigmented-lesions/references/\">Haenssle et al, 2010</a>].<ul><li>Screening by naked-eye examination, the dermatoscopic 7-point checklist, and digital dermatoscopy was carried out over a period of 10 years on 688 people at increased risk of melanoma.</li><li>Of the 127 melanomas detected, 50 were melanoma in situ. In total 79 fulfilled the 7-point checklist threshold of 3 or more points (62% sensitivity, less than in retrospective studies). Specificity was 97% (more than in retrospective studies).</li><li>The sensitivity was increased by the use of complementary information (such as history of the lesion, differences from the person's other moles [ugly duckling sign], and dynamic changes).</li></ul></li><li>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/melanoma-pigmented-lesions/references/\">Walter, 2013</a>] analysed  the use of the Original 7-point checklist with the Weighted 7-point checklist in primary care<ul><li>1580 lesions on 1297 participants were analysed in general practice, showing that both variations performed well in the early identification of melanoma (Comparing lesions scoring 3 points or more from the Original 7-point checklist (sensitivity 80.6% and specificity 61.7%) and the Weighted 7-point checklist (sensitivity 91.7% and specificity 33.1%).</li><li>The term 'irregular border' was noted to be the most important feature, showing a sensitivity of 69.4% and specificity 66.6% alone. </li><li>The study concluded that a potential cut-off score of 4 (rather than 3) may improve specificity for lesions without reducing the sensitivity, although this should be assessed further. </li></ul></li></ul><!-- end field f21cc503-a029-462e-8fd6-d0515557fb7e --><!-- end item 119afb2e-c40e-4d4b-9f85-9ca99b0b02e2 -->","topic":{"id":"f5efb7d1-47fd-5e6a-a34d-95395f7523a0","topicId":"c296c560-d236-46ad-abcc-52c1fc0a1abf","topicName":"Melanoma and pigmented lesions","slug":"melanoma-pigmented-lesions","lastRevised":"Last revised in March 2017","chapters":[{"id":"6f710641-b9e2-5edc-aeed-890a7095cd96","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"88e3acd7-3799-5638-93fc-4739079b0f26","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"4cd2dca8-d311-5805-aea1-3870f6f4fccd","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"4b752af4-f177-5a66-a15f-20135ef4c005","slug":"changes","fullItemName":"Changes"},{"id":"a75a8fa4-d7d6-5932-b9a5-1d5af0bc564e","slug":"update","fullItemName":"Update"}]},{"id":"37450e93-1f0f-5e02-8d33-091798b27dd1","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"37acfb65-9e83-5bb2-b261-3d35d43dc478","slug":"goals","fullItemName":"Goals"},{"id":"c2f69e41-ef64-5440-97db-a9d74ccdb90f","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"d7224a15-69f9-5519-a181-db44131ecc01","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"5489c4c1-2dd5-5679-9dc8-3b4c8136dcb7","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"c5779c9e-ebcd-5682-9817-797e8b88a2f6","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"0f3ef819-faeb-58c1-b3a8-029ddf2d2ec2","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"97595147-c6d8-569e-8edd-b38e54974224","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"b87206e4-fbe6-5ff3-b4db-757e2bdce473","slug":"definition","fullItemName":"Definition"},{"id":"7f5895c0-5070-5a7b-b402-836e18bde1fb","slug":"features","fullItemName":"Features"},{"id":"28380e7d-9dea-5a1f-9be7-1d7ac0e5a123","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"7f9731f8-f8a0-5020-95ad-4220ee1b085a","slug":"prevalence","fullItemName":"Prevalence"},{"id":"fa22327f-becb-5e32-803b-7ff99e765cd1","slug":"prognosis","fullItemName":"Prognosis"},{"id":"ed48057f-9e82-56c6-8846-040b30894b15","slug":"non-melanotic-lesions","fullItemName":"Non-melanotic lesions"},{"id":"aaaf9edb-2903-5b78-831c-b7839586fdfe","slug":"other-pigmented-lesions","fullItemName":"Other pigmented lesions"}]},{"id":"5b41a523-ea89-5f11-bbd5-21118fe0f7b2","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"2a182f91-5ece-564a-a4e3-83ea99005110","slug":"assessment","fullItemName":"Assessment"},{"id":"bb757fc9-32cf-5a88-b59d-3b676b8fe2f0","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"},{"id":"260b59e0-5f81-5189-b2b1-781e2a96257a","slug":"biopsy-of-the-lesion","fullItemName":"Biopsy of the lesion"}]},{"id":"2a84a2c2-8b7a-582d-9ab2-4a4d23728f10","fullItemName":"Management","slug":"management","subChapters":[{"id":"01c409db-6041-5f5d-8faf-ad2b86d6a736","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"b70563d4-10f0-517e-ab86-50e2e260e966","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[{"id":"84e1f7c4-66db-59e5-b9a9-1fc097979aa4","slug":"evidence-on-the-abcd-7-point-checklists","fullItemName":"Evidence on the ABCD and 7-point checklists"},{"id":"68448720-3dbd-530e-bf51-0c8d618ee81e","slug":"evidence-on-self-examination-for-early-melanoma-detection","fullItemName":"Evidence on self-examination for early melanoma detection"}]},{"id":"560a3b23-0b91-5538-a7e7-2b8d61f1dfed","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"9e328671-9080-5494-aeca-8cca3a845389","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"7968cb4d-c0a4-51ae-bc15-16ce3025ca18","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"f3daadc2-eacf-5bcf-8acb-473fa56481df","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"47ede055-d8df-5c65-8d5e-4189da7ac034","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"d2c30ae3-8839-58ef-8a53-f015bff32373","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"02f003b7-53e6-52fe-8c98-bc5580019357","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"b70563d4-10f0-517e-ab86-50e2e260e966","slug":"supporting-evidence","fullItemName":"Supporting evidence"},"subChapters":[]}}},"staticQueryHashes":["3666801979"]}